FREEHOLD, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of precision diagnostic consumer products, today announced a series of Q3 2025 advancements for KetoAir™, including expanded deployment, the launch of a first-responder metabolic health program, and entry into an international market. Key Highlights Launched Holistic Health Reset Program with... Read More

FREEHOLD, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of precision diagnostic consumer products, today announced that it will launch the sales of KetoAir™ breathalyzer device and related accessories in the United Kingdom (“UK”). The products will be available for purchase starting September 1, 2025, at www.KetoAir.uk . KetoAir™ is a handheld... Read More

FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of precision diagnostic consumer products, today announced that its subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation (“Saga Health”) for its use of the KetoAir™ breathalyzer device in its first responder-targeted Holistic Health... Read More

FREEHOLD, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of precision diagnostic consumer products, today announced the issuance of a new standard patent by the Hong Kong Intellectual Property Department (HKIPD) for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. Granted based on a Chinese patent (ZL202080015205.0) and issued as... Read More

FREEHOLD, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of precision diagnostic consumer products, today announced that it entered into a definitive agreement with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis... Read More

FREEHOLD, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, and YOOV Group Holding Limited (“YOOV”), a provider of highly advanced artificial intelligence (“AI”) automation solutions, jointly announced the filing with the U.S. Securities and Exchange Commission... Read More

FREEHOLD, N.J., April 15, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced the addition of SpecialtyHealth, Inc. (“SpecialtyHealth”) — co-founded by Dr. EJ Greenwald, the pioneer of the “Famous Police Panel” — as a strategic partner. SpecialtyHealth will be... Read More

FREEHOLD, N.J., April 10, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, announced today that it has been granted the patent right and Certificate of Invention for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration (CNIPA). The... Read More

FREEHOLD, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products, today announced that it has partnered with Pounds Transformation Clinics, led by Dr. Charles Cavo, a member of the Zero to Keto Affiliate Marketing Program, to launch the “BrAce 4 Impact Challenge... Read More

YOOV Achieves 59.1% Annual Revenue Growth, Reporting Unaudited Revenue of $45.7 Million with Net Income of $3.4 Million for Calendar Year 2024, Versus Unaudited Revenue of $28.7 Million with Net Loss of $2.4 Million for Calendar Year 2023 Upon Consummation of the Merger, Pending Nasdaq Approval, the New Combined Company is Expected to Trade Under the Nasdaq Symbol “YOOV” FREEHOLD, N.J., March 10, 2025 (GLOBE NEWSWIRE) --... Read More

DUBLIN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) ("Fusion Fuel" or the "Company"), a leading provider of gas and hydrogen energy solutions, today announced the appointment of Luisa Ingargiola to its Board of Directors, effective February 24, 2025. Ms. Ingargiola will serve as chairperson of the Audit Committee, replacing Rune Magnus Lundetrae, who will remain a member of the Board. She... Read More

FREEHOLD, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance from the China National Intellectual Property Administration (CNIPA) for its patent application AVAR1901CN. This patent, co-developed with Hong Kong-based Arbele Limited, marks a... Read More

FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on November 19, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule... Read More

FREEHOLD, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced the launch of the "BrAce for Impact" affiliate marketing program for KetoAir™, a handheld breathalyzer device equipped with AI-enabled software and Hot App shareable technology, specifically designed for ketogenic health... Read More

FREEHOLD, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board. Dr. Charles Cavo is the co-founder and Chief Medical Officer of Pounds Transformation, founded to help patients successfully reach... Read More

FREEHOLD, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it entered into a memorandum of understanding (the “MOU”) with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to explore a proposed strategic collaboration to... Read More

FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced that it will effect a 1-for-15 reverse split (“reverse split”) of its common shares that will become effective on October 28, 2024. The Company expects that the reverse stock split will allow the Company to regain... Read More

FREEHOLD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and laboratory services, today announced its participation as an event sponsor at the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, at the Galt House Hotel in Louisville, KY. Avalon will use the event to showcase the KetoAir™ breathalyzer... Read More

FREEHOLD, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has begun manufacturing the GeeWhiz External Condom Catheter, a patented, FDA-registered, in-market, male incontinence device. LSM plans to launch its sales of... Read More

FREEHOLD, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that Laboratory Services MSO, LLC (“LSM”) has launched a direct-to-consumer and non-invasive DNA test in the U.S. that tests for potential predisposition to opioid dependence. To purchase or find out... Read More

FREEHOLD, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of online sales for the KetoAir™ breathalyzer device and related accessories in the U.S. The products are now available at www.ketoair.us . KetoAir™ is a breathalyzer featuring Hot... Read More

FREEHOLD, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today provided an update on the launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference that was held on May 31 to June 2, 2024 in Austin,... Read More

FREEHOLD, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it received a notice (the “Notice”) on May 22, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirements for continued listing under... Read More

FREEHOLD, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference being held from May 31 to June 2, 2024 in Austin, Texas.... Read More

FREEHOLD, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, is pleased to announce the extension of its exclusive distribution agreement with Qi Diagnostics Limited (“Qi Diagnostics”) to distribute the KetoAir™, a breathalyzer device and related accessories, including current... Read More

FREEHOLD, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it engaged ChtrBx , a marketing and branding company, to develop a marketing launch plan for KetoAir™ in North America, South America, the United Kingdom (UK) and the European Union (EU). In... Read More

FREEHOLD, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that it has partnered with Qi Diagnostics Limited (“Qi Diagnostics”) to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for the early detection of diabetic... Read More

KetoAir™ Mobile Application Launches in Apple App Store KetoAir™ Mobile Application also Available in the Google Play Store FREEHOLD, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced the launch of the KetoAir™ mobile application in the Apple App store. The... Read More

FREEHOLD, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing... Read More

FREEHOLD, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc Fusion Water Soluble Receptor Proteins.” The publication... Read More

New Proprietary Testing Method Makes Tuberculosis Diagnosis Easier and Faster New Test Method Expected to Generate Revenue in 2023 FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house... Read More

New Wholly Owned Lab “Veritas Laboratory” of Arizona, Anticipated to Generate Revenue in 2023 Engages Former Congressman Barry M. Goldwater Jr. To Expand Insurance Coverage and Grow Lab Footprint FREEHOLD, N.J., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced... Read More

FREEHOLD, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired DE Laboratory LLC (“DE Labs”), which expands its penetration within Texas and provides significant potential growth opportunities for the combined... Read More

MSA Signed with GeneX Laboratory, an In-Network Laboratory Licensed in Multiple States Including Medicare and Medicaid Laboratory Services MSO will be the Exclusive Testing Provider for Toxicology Testing, Genetic Testing and Others FREEHOLD, N.J., July 19, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative precision diagnostics and provider of clinical... Read More

Company Continues to Implement Major Change in Strategy Focused on Acquiring and Operating Accretive Revenue Generating Laboratories and Related Commercialized Products Company Plans on Developing and Delivering Innovative, Transformative, Precision Diagnostics, Genetic Testing and Clinical Laboratory Services FREEHOLD, N.J., July 10, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT)... Read More

FREEHOLD, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today reported financial results for Laboratory Services MSO, LLC (“LSM”) for the twelve months ended December 31, 2022. In February 2023, Avalon acquired a 40% interest in LSM, a premier clinical diagnostics and... Read More

FREEHOLD, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the commercial launch of the KetoAir™ breathalyzer device and related accessories at the KetoCon Austin 2023 conference, which is being held on April 21-23, 2023 in Austin, Texas. Avalon will showcase... Read More

Commercialization-ready; initially targeting diabetes reversal and weight management markets Coupling diagnostic tools with advanced artificial intelligence software for nutrition management FREEHOLD, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it... Read More

FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has been invited to participate in the 35 th Annual Roth Conference being held on March 13 and 14, 2023. Luisa Ingargiola, Chief Financial Officer of Avalon, will be available... Read More

Transaction Expected to Be Accretive to Earnings Through Profit Sharing Agreement Adds Strong Clinical Synergies to Existing Avalon Portfolio Marks Launch of New Roll-Up Strategy Targeting Toxicology and Pharmacogenetic Laboratories FREEHOLD, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT) , a leading global developer of innovative cell-based technology, cellular... Read More